Novo Nordisk's Wegovy Weight Loss Shot Approved at Higher Dose in EU

Core Insights - A study found that patients on a higher dose of 7.2 milligrams for approximately 18 months experienced an average body weight loss of 21% [1] Group 1 - The dosage of 7.2 milligrams was associated with significant weight loss in patients [1] - The duration of the study was about 18 months, indicating a long-term effect of the treatment [1] - The average weight loss reported was 21%, highlighting the efficacy of the higher dosage [1]